Aligos Therapeutics Inc

NASDAQ:ALGSUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Contact Information

Headquarters

One Corporate Dr., 2nd Floor, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080

Phone

302-658-7581

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Lawrence Blatt

Chief Financial Officer, Executive Vice President

Lesley Calhoun

Executive Vice President, Chief Scientific Officer

Julian Symons

Executive Vice President, Chief Business Officer, General Counsel

Lucinda Quan

Executive Vice President, Chief Medical Officer

Matthew Mcclure